Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
Carlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, Yeh SP, Bouabdallah K, Cartron G, Kim WS, Cordoba R, Koh Y, Re A, Alves D, Chamuleau M, Le Gouill S, López-Guillermo A, Moreira I, van der Poel MWM, Abbadessa G, Meng R, Ji R, Lépine L, Saleem R, Ribrag V. Carlo-Stella C, et al. Among authors: koh y. Hematol Oncol. 2023 Feb;41(1):108-119. doi: 10.1002/hon.3089. Epub 2022 Oct 31. Hematol Oncol. 2023. PMID: 36251503 Free PMC article. Clinical Trial.
Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation.
Jeong SH, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, Lee HW, Eom HS, Won JH, Kim WS, Kim SJ. Jeong SH, et al. Among authors: koh y. Biol Blood Marrow Transplant. 2018 Dec;24(12):2471-2478. doi: 10.1016/j.bbmt.2018.07.034. Epub 2018 Jul 29. Biol Blood Marrow Transplant. 2018. PMID: 30064012 Free article.
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE, Kim SJ, Yoon DH, Koh Y, Mun YC, Do YR, Choi YS, Yang DH, Kim MK, Lee GW, Suh C, Ko YH, Kim WS. Yoon SE, et al. Among authors: koh y. Ann Hematol. 2020 Jun;99(6):1283-1291. doi: 10.1007/s00277-020-04005-6. Epub 2020 Apr 24. Ann Hematol. 2020. PMID: 32333154 Free PMC article. Clinical Trial.
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S, Suzuki K; ICARIA-MM study group. Sunami K, et al. Among authors: koh y. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35641409 Free article.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Facon T, et al. Among authors: koh y. Hematol Oncol. 2022 Dec;40(5):1020-1029. doi: 10.1002/hon.3038. Epub 2022 Jun 8. Hematol Oncol. 2022. PMID: 35653225 Free PMC article.
3,124 results